Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Epizyme Inc (NQ: EPZM )

1.470 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.470
Bid (Size) 1.460 (51)
Ask (Size) 1.470 (263)
Prev. Close 1.470
Today's Range 1.470 - 1.470
52wk Range 0.4110 - 1.580
Shares Outstanding 168,364,752
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Epizyme: Q2 Earnings Insights
  Epizyme (NASDAQ:EPZM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
From Epizyme, Inc.
Via Business Wire

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
+19.51%
+19.51%

More News

Read More
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
From Kahn Swick & Foti, LLC
Via Business Wire
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM
From Kahn Swick & Foti, LLC
Via Business Wire
Why Is Epizyme (EPZM) Stock Up 75% Today?
Via InvestorPlace
Why Epizyme Shares Are Soaring Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Via FinancialNewsMedia
Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Via Benzinga
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Via Benzinga
Epizyme + 20 Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Ipsen to acquire Epizyme, expanding its portfolio in oncology
From Epizyme, Inc.
Via Business Wire
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
20 Stocks Moving in Tuesday's Pre-Market Session
Via Benzinga
93 Biggest Movers From Yesterday
Via Benzinga
91 Biggest Movers From Friday
Via Benzinga
44 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.